Anavex Life Sciences Corp (AVXL) Q2 2025 earnings call Highlights: promising Alzheimer's data …

Appearance date: May 13, 2025

For the complete protocol of the earnings call, see the full profit call transcription.

• Anavex Life Sciences Corp (NASDAQ: AVXL) reported a strong cash position of $ 115.8 million without debts, which offers a financial country road of about four years.

• The company presented promising data on the open label expansion for the treatment of its Alzheimer's and showed considerable clinical advantages over three years.

• The enrollment for the clinical phase -two study by AI 371 in schizophrenia has been successfully completed, with the provisional security and biomarker results encouraged.

• Anavex Life Sciences Corp (NASDAQ: AVXL) expanded his scientific advisory committee with the appointment of Professor Doctor Audrey fork and improves the specialist knowledge in personalized medicine.

• The company is actively preparing for potential European market entry and discusses with potential partners and cros for sales and sales strategies.

• Anavex Life Sciences Corp (NASDAQ: AVXL) reported a net loss of $ 11.2 million for the quarter, which corresponds to $ 0.13 per share.

• The research and development costs rose slightly to $ 9.9 million, which indicates rising costs in their development pipeline.

• The schedule for receiving feedback from the European Medicines Agency (EMA) is uncertain, whereby the expectations for the end of this year or early next quarter are determined.

• The focus of schizophrenia study on security and biomarker effects can delay extensive effectiveness data, since it is primarily a preliminary study.

• There is uncertainty about the schedule for acquisition after approval in Europe, although logistical challenges may affect the introduction.

Q: What is the expected schedule for feedback from the European Medicines Agency (EMA) for the treatment of Alzheimer's? A: Dr. Christopher, CEO, said that after submitting it in November last year until the end of this year or early next quarter, you can expect feedback from EMA. You will report the decision in your final form without preliminary updates.

Q: What are the most important diffraction points for Anavex Life Sciences in 2025, especially in terms of schizophrenia study? A: Dr. Mistling emphasized that the phase -2 study in schizophrenia is the first effectiveness study of 371 and focuses on safety and biomarker effects. The study aims to satisfy the not fulfilled needs, especially in relation to negative symptoms, and will provide the brain with the help of validated biomarkers.